middle.news
How NeuroScientific’s $1.7M Loss Fuels Breakthroughs in Crohn’s and Glaucoma Treatments
9:02pm on Wednesday 25th of February, 2026 AEDT
•
Healthcare
Read Story
How NeuroScientific’s $1.7M Loss Fuels Breakthroughs in Crohn’s and Glaucoma Treatments
9:02pm on Wednesday 25th of February, 2026 AEDT
Key Points
Net loss widened to $1.7 million for H1 FY2026
Initiated clinical treatments under TGA Special Access Scheme for Crohn’s disease
Advanced pre-clinical development of EmtinB for glaucoma
New CEO and Chief Medical Officer appointed to strengthen leadership
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NEUROSCIENTIFIC BIOPHARMACEUTICALS (ASX:NSB)
OPEN ARTICLE